KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

Historic Receivables - Other for AbCellera Biologics (ABCL) over the last 2 years, with Q2 2021 value amounting to $62.1 million.

  • AbCellera Biologics' Receivables - Other changed N/A to $62.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $62.1 million, marking a year-over-year change of. This contributed to the annual value of $212.3 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that AbCellera Biologics reported Receivables - Other of $62.1 million as of Q2 2021.
  • Over the past 5 years, AbCellera Biologics' Receivables - Other peaked at $212.3 million during Q4 2020, and registered a low of $62.1 million during Q2 2021.